Some US employers are expected to drop coverage for weight-loss drugs in 2027. This decision is reportedly due to financial challenges.

GLP-1 drugs are increasingly being used, which may be contributing to these financial difficulties for employers. Their growing use is also affecting the health care and business landscape.

Further information on this development is available from the source, including details on the impact of GLP-1 drugs on employers and the health care system.